CAPR → $35.00 by Oct 15, 2026.

$CAPR is shaping up for a potential repeat of what we saw in November. Short interest has climbed back above 30% of the float, sentiment around FDA approval has pushed the stock down to levels that seem to reflect a meaningful chance of rejection, and despite the positive data already released, the market is still leaving roughly $8–10/share of upside on the table if approval expectations improve. With 7 days to cover, any positive update from the upcoming FDA meetings …